| 1 |
35523987 | Discovery of novel targets and mechanisms of MEK inhibitor Selumetinib for LGG treatment based on molecular docking and molecular dynamics simulation. | 2022 May 6 |
1 |
| 2 |
33416182 | Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells. | 2021 Feb |
1 |
| 3 |
34666331 | The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calreticulin Gene Mutation. | 2021 |
1 |
| 4 |
29928418 | Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation. | 2018 Jul |
2 |
| 5 |
30021885 | PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. | 2018 Jul 18 |
1 |
| 6 |
30343534 | Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition. | 2018 Dec |
1 |
| 7 |
28982310 | The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells. | 2017 Oct |
1 |
| 8 |
26601868 | Treatment of Uveal Melanoma. | 2016 |
1 |
| 9 |
27422710 | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. | 2016 Oct |
1 |
| 10 |
25342139 | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. | 2015 Feb |
5 |
| 11 |
25933683 | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. | 2015 Jul |
1 |
| 12 |
25959272 | EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. | 2015 Dec |
2 |
| 13 |
26137449 | Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. | 2015 |
1 |
| 14 |
26250606 | Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer. | 2015 Nov |
3 |
| 15 |
23443802 | Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. | 2013 May |
1 |
| 16 |
23444215 | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. | 2013 Apr 15 |
1 |
| 17 |
23602735 | Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. | 2013 Oct |
1 |
| 18 |
22082529 | Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. | 2012 Mar |
2 |
| 19 |
22090271 | The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. | 2012 Feb |
1 |
| 20 |
21628402 | The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. | 2011 Jul 28 |
1 |
| 21 |
21828154 | Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. | 2011 Sep 14 |
2 |
| 22 |
20885957 | Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. | 2010 Sep 27 |
2 |
| 23 |
20959481 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. | 2010 Nov 1 |
7 |
| 24 |
21124782 | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. | 2010 Nov 29 |
3 |
| 25 |
19755509 | Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. | 2009 Sep |
1 |
| 26 |
19783898 | High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). | 2009 Nov |
4 |